Research programme: antibody-drug conjugates - Ambrx

Drug Profile

Research programme: antibody-drug conjugates - Ambrx

Alternative Names: αCD3-folate; αCD70-ADC; αPSMA-ADC

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator Ambrx
  • Class Drug conjugates; Immunoconjugates; Pterins; Vitamins
  • Mechanism of Action CD3 antigen modulators; CD70 antigen modulators; Glutamate carboxypeptidase II modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • Research Cancer

Most Recent Events

  • 26 Nov 2015 Preclinical trials in Inflammation in USA (unspecified route) before November 2015
  • 31 Dec 2013 Early research in Inflammation in USA (unspecified route)
  • 31 Dec 2013 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top